Trials / Completed
CompletedNCT01467661
Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia
A Phase 3, Multi-centre, Open-label, Extension Study to Investigate the Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to provide SPD422 to subjects who completed Study SPD422 308 and, in the opinion of the Investigator, will continue to benefit from treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPD422 (anagrelide hydrochloride) | Subjects will be continued on the dose of anagrelide that controlled their platelet levels in Study 308 and titrated if necessary. |
Timeline
- Start date
- 2010-10-27
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2011-11-09
- Last updated
- 2021-06-09
- Results posted
- 2016-06-08
Locations
16 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01467661. Inclusion in this directory is not an endorsement.